Pfizer has received FDA priority review for a supplemental biologics license application to expand the indication of Hympavzi (marstacimab).
The proposed label expansion would include patients with hemophilia A or B ages 6 and older with inhibitors and pediatric patients ages 6-11 without inhibitors, according to a Feb. 6 company news release. Hympavzi is currently approved in the U.S. to treat individuals ages 12 and older with hemophilia A or B without inhibitors.
If approved, Hympavzi would be the first non-factor prophylactic treatment for children ages 6-11 with hemophilia B. The FDA assigned a Prescription Drug User Fee Act action date in the second quarter of 2026.
Pfizer leaders said the treatment could become a transformative option for populations with limited or burdensome therapies.
The supplemental biologics license application is supported by data from Pfizer’s phase 3 BASIS and BASIS KIDS trials. The FDA previously granted Hympavzi Breakthrough Therapy Designation for routine prophylaxis in children ages 6 to younger than 12 with hemophilia B with or without inhibitors.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
